News
Resources
Blog
Sites
Megan Van Etten Megan Van Etten is senior director of public affairs at PhRMA. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Recent Posts
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
By Megan Van Etten | February 24, 2022
Biopharmaceutical companies are working across the industry and around the world to meet the global demand for COVID-19 vaccines. Companies have continued to ramp up their efforts to source needed...
Read More
Patients and innovators lose if the government pursues ‘march-in’
By Megan Van Etten | September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
Driving further innovation is critical to global vaccine equity
By Megan Van Etten | August 24, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Supporting country readiness to boost global vaccine access
By Megan Van Etten | August 12, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.
Read More
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
By Megan Van Etten | August 5, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Increasing global access to vaccines by optimizing production
By Megan Van Etten | July 29, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.
Read More
Dose sharing as a part of the COVID-19 global vaccine equity strategy
By Megan Van Etten | July 20, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Promoting global vaccine equity while protecting innovation
By Megan Van Etten | July 15, 2021
America’s biopharmaceutical companies have successfully researched, developed and distributed billions of doses of multiple vaccines and therapeutics to halt the spread of COVID-19. The availability...
Read More
IP Explained: How does the U.S. patent process work?
By Megan Van Etten | June 24, 2021
Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...
Read More
Supporting India during the devastating coronavirus surge
By Megan Van Etten | May 20, 2021
Like many others around the world, America’s biopharmaceutical companies stand with those affected by the coronavirus. And while biopharmaceutical companies are working around the clock to meet the...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
